Market Cap 713.82M
Revenue (ttm) 0.00
Net Income (ttm) -38.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 233,700
Avg Vol 333,112
Day's Range N/A - N/A
Shares Out 52.03M
Stochastic %K 54%
Beta 0.97
Analysts Strong Sell
Price Target $30.50

Company Profile

GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression. The...

Industry: Biotechnology
Sector: Healthcare
Phone: 353 1 437 8334
Address:
Joshua Dawson House, Dawson Street, Dublin, Ireland
TimRegan_WTR
TimRegan_WTR Nov. 14 at 3:25 PM
0 · Reply
research_WTR
research_WTR Nov. 14 at 10:28 AM
In our latest WTR Healthcare Happenings Flashcast, hosts Tim Gerdeman and Robert Sassoon break down the latest developments shaping the therapeutic psychedelics investment landscape. 🔹 October’s fundraising surge marks the strongest quarter since 2021, signaling renewed investor confidence 🔹 Sector shifts from hype-driven speculation to data-backed optimism and late-stage clinical progress 🔹 Discussion of valuation trends, capital flows, and sustainability of momentum into 2026 🔹 How pharma partnerships and clinical validation are reshaping the narrative for psychedelic medicine Tune in now for expert insights on the sector’s next growth phase. Podcast Platforms: https://pod.link/1795488592 Website: https://www.watertowerresearch.com/media-detail/2764/Media #Psychedelics #HealthcareInvesting #MentalHealth #Biotech #LifeSciences #WTRHealthcareHappenings $CYBN $MNMD $CMPS $GHRS $MDMA
0 · Reply
Doozio
Doozio Nov. 12 at 4:31 PM
$GHRS 🐒🍌🧠⏰♾️
0 · Reply
JarvisFlow
JarvisFlow Nov. 10 at 5:10 PM
HC Wainwright & Co. has updated their rating for GH Research ( $GHRS ) to Buy with a price target of 35.
1 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 5 at 10:35 PM
0 · Reply
stoxx0007
stoxx0007 Nov. 5 at 8:46 PM
1 · Reply
outlawinvestor1
outlawinvestor1 Nov. 3 at 5:10 PM
$CYBN $ATAI $GHRS probably a good time to buy cybin, given biotech funds recently purchased at $6.50/sh, company raised $175 million (current cash: ~$270 million), mc = $185 million. a biotech company with two late stage assets with readouts in q1 (ph2 gad) and q4 2026 (ph3 md).
1 · Reply
W15E
W15E Nov. 2 at 5:44 PM
$GHRS very much worth watching
0 · Reply
outlawinvestor1
outlawinvestor1 Oct. 28 at 12:53 PM
$CYBN nice. the big funds want in now. this should be good for the entire pscyh industry and bring $CYBN o/s to ~48 million shares. $ATAI $GHRS.
1 · Reply
Latest News on GHRS
GH Research Announces Pricing of $150 Million Public Offering

Feb 4, 2025, 8:52 PM EST - 10 months ago

GH Research Announces Pricing of $150 Million Public Offering


GH Research Announces Proposed Public Offering

Feb 3, 2025, 4:03 PM EST - 10 months ago

GH Research Announces Proposed Public Offering


Why Is GH Research Stock Trading Higher On Monday?

Feb 3, 2025, 10:55 AM EST - 10 months ago

Why Is GH Research Stock Trading Higher On Monday?


GH Research to Provide Update on Phase 2b Trial with GH001 in TRD

Jan 31, 2025, 4:01 PM EST - 10 months ago

GH Research to Provide Update on Phase 2b Trial with GH001 in TRD


GH Research: But Toad Venom Is A Controlled Substance

Jun 16, 2023, 11:06 AM EDT - 2 years ago

GH Research: But Toad Venom Is A Controlled Substance


Psychedelic Sunday: Competitive Strategies

Jan 15, 2023, 11:45 AM EST - 3 years ago

Psychedelic Sunday: Competitive Strategies

ATAI CMPS CYBN MNMD


GH Research Seeks $125 Million IPO

Jun 22, 2021, 8:25 PM EDT - 4 years ago

GH Research Seeks $125 Million IPO


TimRegan_WTR
TimRegan_WTR Nov. 14 at 3:25 PM
0 · Reply
research_WTR
research_WTR Nov. 14 at 10:28 AM
In our latest WTR Healthcare Happenings Flashcast, hosts Tim Gerdeman and Robert Sassoon break down the latest developments shaping the therapeutic psychedelics investment landscape. 🔹 October’s fundraising surge marks the strongest quarter since 2021, signaling renewed investor confidence 🔹 Sector shifts from hype-driven speculation to data-backed optimism and late-stage clinical progress 🔹 Discussion of valuation trends, capital flows, and sustainability of momentum into 2026 🔹 How pharma partnerships and clinical validation are reshaping the narrative for psychedelic medicine Tune in now for expert insights on the sector’s next growth phase. Podcast Platforms: https://pod.link/1795488592 Website: https://www.watertowerresearch.com/media-detail/2764/Media #Psychedelics #HealthcareInvesting #MentalHealth #Biotech #LifeSciences #WTRHealthcareHappenings $CYBN $MNMD $CMPS $GHRS $MDMA
0 · Reply
Doozio
Doozio Nov. 12 at 4:31 PM
$GHRS 🐒🍌🧠⏰♾️
0 · Reply
JarvisFlow
JarvisFlow Nov. 10 at 5:10 PM
HC Wainwright & Co. has updated their rating for GH Research ( $GHRS ) to Buy with a price target of 35.
1 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 5 at 10:35 PM
0 · Reply
stoxx0007
stoxx0007 Nov. 5 at 8:46 PM
1 · Reply
outlawinvestor1
outlawinvestor1 Nov. 3 at 5:10 PM
$CYBN $ATAI $GHRS probably a good time to buy cybin, given biotech funds recently purchased at $6.50/sh, company raised $175 million (current cash: ~$270 million), mc = $185 million. a biotech company with two late stage assets with readouts in q1 (ph2 gad) and q4 2026 (ph3 md).
1 · Reply
W15E
W15E Nov. 2 at 5:44 PM
$GHRS very much worth watching
0 · Reply
outlawinvestor1
outlawinvestor1 Oct. 28 at 12:53 PM
$CYBN nice. the big funds want in now. this should be good for the entire pscyh industry and bring $CYBN o/s to ~48 million shares. $ATAI $GHRS.
1 · Reply
stoxx0007
stoxx0007 Oct. 26 at 2:23 AM
0 · Reply
james2609
james2609 Oct. 25 at 6:06 AM
$GHRS buyout Monday
0 · Reply
patience_pays1
patience_pays1 Oct. 24 at 4:24 PM
$GHRS lets get buyout
1 · Reply
Doozio
Doozio Oct. 15 at 10:21 PM
$GHRS chop chop huckleberries……
0 · Reply
stoxx0007
stoxx0007 Oct. 14 at 11:50 PM
$GHRS $MNMD $CYBN $CMPS $PSIL Very Bold prediction right here.... And I agree 💯% ... 1,000% !!!🔥
0 · Reply
JarvisFlow
JarvisFlow Oct. 13 at 10:11 AM
Needham updates rating for GH Research ( $GHRS ) to Buy, target set at 19.
0 · Reply
radhaswami8380
radhaswami8380 Oct. 9 at 12:31 PM
$NRXP The presentation yesterday was a hit with new investors, and we expect an announcement very soon. It's all about timing, and right now, the momentum is on our side. Just look at the string of good news from last month—this is another chance to get in on the ground floor. This stock is poised for a major move, with the potential to jump 20-25% in a day and continue climbing. The $40 price target isn't a guess; it's based on solid research. Remember, you can't rush a ripe mango. Great returns require patience, but for those who wait, the reward will be worth it. $GHRS $HUMA $ATAI
3 · Reply
Jason7847
Jason7847 Oct. 6 at 2:53 PM
$NRXP 1) NRx Pharmaceuticals’ recent FDA Fast Track designation for NRX-100 marks a major milestone that could accelerate the path to commercialization. 2) The company’s focus on innovative treatments for depression and suicidal ideation positions it as a potential leader in a critical and underserved market. 3) With growing regulatory momentum and strong clinical progress, NRXP appears well-placed to capture investor attention and long-term value. 4) Strategic partnerships and expanding clinical data could significantly enhance NRXP’s market credibility and growth prospects. 5) As mental health therapeutics gain global importance, NRx’s advanced drug pipeline represents a high-impact investment opportunity. 6) Positive FDA engagement and clinical advancements underscore NRXP’s potential for near-term catalysts and long-term growth. $ATAI $ICU $HUMA $GHRS
1 · Reply
Jason7847
Jason7847 Oct. 2 at 5:32 PM
$NRXP $6 by month-end, 200% upside possible by year-end. Big catalysts ahead. $ATAI $ICU $HUMA $GHRS
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 2 at 8:39 AM
$GHRS Excellent article that nails exactly where GHRS stands right now. So if you want to update your GHRS knowledge or get acquainted with GHRS, this is a must read. https://beyondspx.com/quote/GHRS/analysis/gh-research-pioneering-psychedelic-therapies-for-depression-s-unmet-needs-nasdaq-ghrs
0 · Reply
TalkMarkets
TalkMarkets Oct. 1 at 10:46 PM
Top 4 "Psych" Stocks Went Crazy In September Going Up +18% - Here's Why $ATAI $MNMD $CMPS $GHRS https://talkmarkets.com/content/stocks--equities/top-4-psych-stocks-went-crazy-in-september-going-up-18-heres-why?post=525544
0 · Reply
Raxothus
Raxothus Sep. 29 at 7:55 PM
EOD CONTINUATION FOLLOW-UP – 09/29/25 Tracking continuation watchlist from today based on intraday highs vs. close ❌ $MTEK – Dumped from 4.27 into the 2s on bad earnings. Full fade, failed continuation. ⚠️ $JUNS – Closed 1.60, reached 1.80 (+12.5%). Slow continuation, needs volume confirmation. ⚠️ $PRLD – Sideways action. No decisive continuation yet. ❌ $ELDN – Closed 2.67, slipped to 2.52. Weak, failed continuation. ⚠️ $GHRS – Sideways action. Neutral, watching for setup. Recap: 5 total → 1 winner, 2 fails, 2 neutral → 20% accuracy Leader: $JUNS (+12.5%) is the only valid continuation candidate, though momentum remains slow. #VWAP #SmallCaps #DayTrading #EODFollowUp #Continuation #SniperSetup #Accountability
0 · Reply